| アブストラクト | We commend Liang et al for shining a spotlight on second primary malignancies after bispecific antibody (BsAb) therapy, yet several clinical nuances deserve consideration. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)-derived case-fatality rates likely overstate risk, prior genotoxic treatments confound causality, and pooling heterogeneous BsAb constructs may blur construct-specific signals. The 124-day median latency hints at misclassification, while sparse African data limit global relevance. Risk-adapted surveillance-grounded in clonal haematopoiesis, prior cytotoxic exposure and BsAb construct-may be more pragmatic than blanket monitoring. |
|---|
| ジャーナル名 | Journal for immunotherapy of cancer |
|---|
| Pubmed追加日 | 2025/5/9 |
|---|
| 投稿者 | Jin, Yan; Jin, Yongli; Cui, Yan; Zheng, Rongzhen |
|---|
| 組織名 | Department of Hemodialysis Room, Yanbian University Hospital, Yanji, China.;Department of Anesthesiology, Yanbian University Hospital, Yanji, China.;Department of Oncology, Yanbian University Hospital, Yanji, China.;Department of Anesthesiology, Yanbian University Hospital, Yanji, China;Zhengrongzhen2005@163.com. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/40341030/ |
|---|
